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Abstract
Background: Endometrial cancer is the most common gynecologic malignancy in Puerto Rico and the United
States (US).
Methods: We compare the age-specific and age-adjusted incidence and mortality rates and the survival of
endometrial cancer in Puerto Rico with that of non-Hispanic whites (NHW), non-Hispanic blacks (NHB) and
Hispanics in the US. Data from the Puerto Rico Central Cancer Registry and the Surveillance, Epidemiology, and
End Results program were analyzed from 1992-2003.
Results: Age-standardized incidence rates of endometrial cancer increased significantly (p < 0.05) in Puerto Rico
(APC = 2.8%) and among NHB (APC = 1.9%) and remained constant (p > 0.05) for NHW (APC = -0.1%) and
Hispanics in the US (APC = 0.4%). Mortality trends remained constant in all racial/ethnic groups (p > 0.05). For
1999-2003, women in Puerto Rico had similar incidence of endometrial cancer as Hispanics (Standardized rate ratio
[SRR] = 0.94, 95% CI = 0.87-1.01), although their risk was lower than that of NHW (SRR = 0.56, 95% CI = 0.53-0.59)
and NHB (SRR = 0.91, 95% CI = 0.84-0.98). Meanwhile, women in Puerto Rico had 15% higher risk of death than
Hispanic women (SRR = 1.15, 95% CI = 1.03-1.30) similar risk than NHW (SRR = 0.93, 95% CI = 0.83-1.03), and lower
risk than NHB (SRR = 0.51, 95% CI = 0.46-0.57). Puerto Rico (63.1%) and NHB (56.8%) had a lower 5-year survival
than NHW (78.4%) and Hispanics (79.5%). An age-adjusted Cox proportional hazards model showed that compared
with women in Puerto Rico, Hispanic women in the United States had 37% lower mortality risk (HR = 0.63, 95% CI
= 0.56-0.71) and NHW had 53% lower mortality risk (HR = 0.47, 95% CI = 0.43-0.52) after 5 years of diagnosis; NHB
women had 22% higher mortality risk than women in Puerto Rico (HR = 1.22, 95% CI = 1.09-1.36).
Conclusions: The lower burden of endometrial cancer in Puerto Rico suggests the presence of protective factors
or lower exposure to risk factors in this population, although increases in incidence suggest changes in the
occurrence of lifestyles and environmental risk factors. Meanwhile, the lower five-year survival from endometrial
cancer among Puerto Ricans suggests a health disparity for this group in areas such as quality of care and/or
differences in terms of stage at diagnosis and associated comorbidities. Assessment of disease risk factors and
characteristics, and access and response to treatment is required to further understand these results.
Background
Uterine cancer is the most common gynecologic malig-
nancy in Puerto Rico and the United States. In the Uni-
ted States, uterine cancer is the fourth most common
cancer in women, accounting for approximately 6% of
all cancers [1,2]. In Puerto Rico, uterine cancer is the
third most common cancer type, also representing
approximately 6% of all cancers [3]. Despite the impor-
tance of this malignancy among Puerto Rican women,
there is no recently published data on the burden of
endometrial cancer in Puerto Rico. Previous studies in
the 70’sa n d8 0 ’s showed a lower incidence of the dis-
ease among women living in Puerto Rico as compared
to the general population in the United States [4] and to
Puerto Ricans [5] living in the continental United States.
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corpus uterus in the United States has focused mainly
on non-Hispanic whites (NHW) and non-Hispanic
Blacks (NHB), with fewer comparisons with other
racial/ethnic groups, such as Hispanics [6]. Although
Puerto Rico is a Commonwealth territory of the United
States since 1898, cancer data for Puerto Rico is not
currently included in the United States cancer statistics
[7]. Knowledge of the burden of cancer in specific
populations is important to identify health disparities
among populations [7]. To further our understanding
of the burden of endometrial cancer in Puerto Rico
and how it compares with other racial/ethnic groups
in the United States, we compare the age-specific and
age-adjusted incidence and mortality rates and the sur-
vival of endometrial cancer in Puerto Rico with that of
Hispanics, NHW, and NHB in the United States for
the period 1992-2003, years in which the National
Cancer Institute’s Surveillance, Epidemiology, and End
Results program [SEER] first began coding Hispanic
ethnicity.
Methods
Data Sources
Incident data of endometrial cancer for Puerto Rico
were obtained from the incidence case file [8] from
1992-2003. The Puerto Rico Central Cancer Registry is
the fourth oldest population-based cancer registry in the
world [9] collecting information in Puerto Rico since
1951. Since 1997, the Puerto Rico Central Cancer Regis-
try has been part of the CDC’s National Program of
Cancer Registry and uses the SEER and the North
American Association of Central Cancer Registries
(NAACCR) standards for coding data; thus, the registry
is fully comparable with both SEER and NAACCR data.
In the year 2003, a CDC audit concluded that 95.3% of
all cancer cases diagnosed or treated in hospital facilities
in Puerto Rico were appropriately reported to the
Puerto Rico Central Cancer Registry; a result compar-
able to the United States median (95%) [10]. All cancer
cases diagnosed since 2001 are reported using the third
edition of the International Classification of Disease for
Oncology (ICD-O-3) [11]. Cases from 1992 to 2000
which were originally reported using previous editions
of ICD-O were converted to ICD-O-3 codes. Incident
cases of endometrial cancer for NHW, NHB, and Hispa-
nics in the United States for the period from 1992 to
2003 were obtained from the SEER 13 [SEER Stat 6.3.5
software] [12].The database SEER 13 represents 13.8%
of the total US population; the Hispanic category repre-
sents 21.8% of the total US Hispanic population and
includes persons from multiple Hispanic sub-groups (i.e.
Mexicans, Puerto Ricans, Cubans, among others living
in the US). Incidence data for Hispanics are based on
the NAACCR Hispanic Identification Algorithm (NHIA)
[13].
Endometrial cancer mortality information for Puerto
Rico and the United States (NHW, NHB, Hispanics)
from 1992-2003 was obtained, respectively, from the
Puerto Rico Central Cancer Registry as reported by
death certificates prepared by the Puerto Rico Depart-
ment of Health [14] and from the SEER program as
reported by the National Center for Health Statistics
(NCHS) [15]. Causes of death were coded and classified
according to the International Classification of Diseases
(ICD-10) [16].
Women diagnosed with a primary cancer of the endo-
metrium (ICD-O3 C54.1 with histological valid codes
from 8000-8576 or by death certificate from cancer
associated to the endometrium or corpus and uterus,
not otherwise specified (NOS) (ICD-10 C54-C55; ICD-9
179, 182)), between 1992 and 2003 were eligible for our
study. For incidence statistics, the analysis was limited
to primary cases of malignant endometrial cancer con-
firmed microscopically, with a positive histology, positive
exfoliative cytology with no positive histology, a positive
laboratory test/marker study or direct visualization with-
out microscopic confirmation, radiography without
microscopic confirmation, clinical diagnosis only or
those diagnosed solely by death certificates. Cases of
carcinoma in situ and uterine sarcomas were excluded.
For mortality statistics, cases with cause of death stated
as corpus and uterus, NOS were eligible for analysis.
Mortality from endometrial cancer was evaluated com-
bining corpus and NOS categories as these categories
are usually combined to reflect non-cervical carcinoma
of the uterus and given that cases diagnosed through
death certificates are more likely to have NOS classifica-
tion. Data quality across all sub-groups was good, as the
proportion of death certificate only cases was low across
all racial/ethnic groups (<1%) (data not shown).
Statistical Analysis
Incidence and mortality rates
We calculated the age-specific annual incidence and
mortality rates of endometrial cancer (per 100,000
women) and their 95% confidence intervals (CI) for
women aged 20 years and older for Puerto Rico and the
following mutually exclusive racial/ethnic groups in the
United States: NHW, NHB and Hispanics. Age-specific
incidence rates by racial/ethnic group were calculated by
dividing the annual number of cases in each age and
racial/ethnic group by the estimated annual total popu-
lation of women in the same age and racial/ethnic
group. Age-specific mortality rates in each racial/ethnic
group were calculated similarly using age-specific cases
of endometrial cancer deaths and the number of women
who died from other causes in each age group. Age-
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nic group were then age-standardized by the direct
method to the 2000 Standard Population of the United
States, provided by Census Bureau [17,18]. The annual
percent change (APC) was estimated to evaluate overall
and age-specific incidence and mortality trends of endo-
metrial cancer from 1992 to 2003 using SEER*Stat Soft-
ware and Joinpoint Regression software program 3.0
[19]. This calculation involved fitting a least squares
regression line to the natural logarithm of the rates in
each ethnic group, using the calendar year as a regressor
variable.
To assess racial/ethnic group differences, the inci-
dence and mortality rates were grouped from 1999-
2003. Then, the ratio of two standardized rates was esti-
mated with its 95% confidence interval [20], to assess
significant differences in endometrial cancer between
persons living in Puerto Rico and Hispanics, NHW and
NHB in the United States, using the STATA System
release 10.0 (STATA Corp, College Station, TX, United
States). These ratios were denoted as incidence and
mortality standardized rate ratios (SRR).
Survival
The 5-year observed survival curves for women aged 20
years and older were calculated from 1992-2002 for
each racial/ethnic group using the incidence case files of
Puerto Rico and the SEER 17. Survival curves by racial/
ethnic group were estimated using the Kaplan-Meier
method [21] and differences between survival curves
were assessed using the log-rank test [22], using SAS
9.1. Cases lost to follow up and those alive at the end of
the follow-up period (December 31, 2004) were consid-
ered censored observations. In addition, cases with a
death after the 5-year follow-up interval were considered
alive at the end of those 5 years. A Cox-proportional
hazards model was used to compare the 5-year endome-
trial cancer survival by racial/ethnic groups while adjust-
ing for age at diagnosis [21,22].
Results
Incidence and mortality rates
From 1992 to 2003, the age-standardized incidence rates
of endometrial cancer in Puerto Rico for women aged
20 years and older increased significantly among Puerto
Ricans (14.3 in 1992 to 19.5 in 2003) and NHB (16.6 in
1992 to 21.1 in 2003); an average increase of 2.8% per
year in Puerto Rico and 1.9% per year in NHB (Table
1). Rates remained relatively constant for NHW (32.2 in
1992 to 32.1 in 2003) and Hispanics (18.9 in 1992 to
20.7 in 2003) in the United States; with non-significant
changes in the APCs in these groups (p > 0.05). Women
in Puerto Rico, aged 20 to 34 years, (APC = 9.2%)
showed the fastest increase in incidence, from 0.2 per
100,000 in 1992 to 3.0 per 100,000 in 2003 (p < 0.05).
Increases in incidence were also observed among NHW
(APC = 6.4%), Hispanics (APC = 4.4%) and NHB (APC
= 10.5%) women aged 20-34 years, although these were
not statistically significant among Hispanics in the Uni-
ted States. The number of cases for this age group was
relatively small (cases fluctuated from 1 to 13 for PR,
f r o m2t o1 1f o rN H B ,f r o m9t o2 3f o rH i s p a n i c sa n d
from 12 to 25 among NHW), thus, the APC need care-
ful interpretation. Meanwhile, in all racial/ethnic groups,
overall mortality rates for endometrial cancer remained
constant from 1992-2003 (p > 0.05) (Table 2). In age
stratified analysis, the only significant decreases in endo-
metrial cancer mortality were observed among NHW
women aged 65-79 years (APC = -0.7%) and those aged
80+ (APC = -0.6%) (p < 0.05).
For 1999-2003, the SRR showed that women in
Puerto Rico had similar risk of endometrial cancer as
compared to Hispanics in the United States (SRR =
0.94, 95% CI = 0.87-1.01), although lower risk than that
of NHW (SRR = 0.56, 95% CI = 0.53-0.59) and NHB
(SRR = 0.91, 95% CI = 0.84-0.98) in the United States.
Regarding mortality, the SRR showed that women in
Puerto Rico had 15% higher risk of death from endome-
trial cancer than Hispanic women (SRR = 1.15, 95% CI
= 1.03-1.30), similar risk than NHW (SRR = 0.93, 95%
CI = 0.83-1.03), and lower risk than NHB (SRR = 0.51,
95% CI = 0.46-0.57) (Table 3).
5-year survival
The observed 5-year survival from endometrial cancer
was 78.4% (95% CI = 77.9%-78.9%) among NHW,
79.5% (95% CI = 77.9%-81.0%) among Hispanics, 63.1%
(95% CI = 60.1%-65.9%) in Puerto Rico and 56.8 (95%
CI = 54.7%-58.9%) for NHB (Figure 1). Significant dif-
ferences in the survival curves were observed across
racial/ethnic groups (Log-rank X
2 = 817.94, p <.0001),
with the 20
th percentile of the survival function (based
on the failure probability) being higher for Hispanics
and NHW (58 and 53 months, respectively) than for
NHB and Puerto Ricans (14 and 23 months, respec-
tively) (data not shown). Thus, in NHB and Puerto
Ricans there is more than a 20% probability of death
by months 14 and 23 after endometrial cancer diagno-
sis, respectively. Meanwhile, for Hispanics and NHW
there is more than a 20% probability of death by
months 55 and 51, correspondingly. In addition, the
age-adjusted Cox proportional hazards model showed
that compared with women in Puerto Rico, Hispanic
women in the United States had 37% lower mortality
risk4(HR = 0.63, 95% CI = 0.56-0.71) and NHW had
53% lower mortality risk (HR = 0.47, 95% CI = 0.43-
0.52) after 5 years of diagnosis. NHB women had 22%
higher mortality risk than women in Puerto Rico (HR
= 1.22, 95% CI = 1.09-1.36).
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Incidence and mortality rates
Puerto Rican women showed a significant increase in
the incidence of endometrial cancer during the study
period; this rapid increase suggests changes in environ-
mental exposures and lifestyle factors within this popu-
lation. Obesity and diabetes, two of the major risk
factors associated with endometrial cancer [2], have
increased among Puerto Rican women in the last decade
[23,24]. Moreover, although the prevalence of obesity in
Puerto Rican women (22.3%) is similar to that in the
United States, the prevalence of diabetes in Puerto Rico
(12.5%, 95% CI = 11.3%-13.7%) is the highest of all
states and territories in the United States [23]. In addi-
tion, other factors related to Western lifestyle, such as
sedentary behavior, low physical activity and changes in
dietary factors (i.e. low fruit and vegetable consumption)
may also contribute to the increased incidence [23,24].
Similar increases have been observed in Puerto Rico on
the incidence of breast [25] and colorectal [26] cancer
and support the notion that as our population acquires
Western lifestyles, cancer risk is likely to follow those of
industrialized societies. The fastest increase in the inci-
dence of endometrial cancer observed among women
aged 20-34 years in Puerto Rico from 1992 to 2003 is of
special interest as this is not a common event among
younger women [27]. This increasing trend in incidence
was also observed among NHW, NHB, and Hispanic
w o m e ni nt h eU n i t e dS t a t e s .A g a i n ,s o m eo ft h es t r o n -
gest identified risk factors for endometrial cancer, obe-
sity and diabetes [2] have increased among young
Puerto Rican and United States cohorts (25-34 years),
and may account for this increase among young women
[23,24]. Nonetheless, these results need to be interpreted
with caution, as the number of cases for this age group
was relatively small across all racial/ethnic groups.
Other potential explanations for the increase in endo-
metrial cancer incidence rates are the changes in hor-
monal and reproductive factors, such as parity and age
at menarche [2], over the last decades in Puerto Rico.
Fertility rate among Puerto Rican women has decreased.
The average number of children born to women 15 to
Table 1 Age-adjusted and age-specific incidence rates and trends from endometrial cancer by racial/ethnic group,
1992-2003
a
Puerto Rico NHW NHB Hispanics
Year: 1992
Age-adjusted rate × 100,000
(95% CI)
a, b 14.3 (12.2-16.7) 32.2 (31.0-33.4) 16.6 (14.2-19.3) 18.9 (16.4-21.7)
Age-specific rate (95% CI)
20-34 years 0.2 (0.0-1.3) 0.5 (0.2-0.8) 0.4 (0.0-1.4) 1.5 (0.8-2.6)
35-49 years 6.4 (4.1-9.6) 10.7 (9.5-12.0) 4.5 (2.7-7.1) 10.6 (8.0-13.8)
50-64 years 28.3 (22.0-35.8) 59.6 (55.8-63.5) 22.3 (16.4-29.6) 29.8 (23.3-37.5)
65-79 years 37.2 (28.1-48.4) 101.7 (96.4-107.3) 61.7 (49.2-76.4) 55.7 (43.4-70.4)
80+ years 31.1 (17.0-52.1) 67.0 (60.1-74.4) 50.9 (31.1-78.6) 26.3 (12.0-49.9)
Year: 2003
Age-adjusted rate × 100,000
(95% CI)
a, b 19.5 (17.3-21.9) 32.1 (31.0-33.2) 21.1 (18.7-23.7) 20.7 (18.6-22.9)
Age-specific rate (95% CI)
20-34 years 3.0 (1.6-5.2) 1.2 (0.8-1.8) 0.8 (0.2-2.0) 1.9 (1.2-2.9)
35-49 years 9.3 (6.6-12.7) 12.9 (11.6-14.4) 7.5 (5.3-10.2) 11.0 (8.9-13.6)
50-64 years 38.3 (31.9-45.5) 63.2 (59.9-66.7) 35.4 (29.2-42.6) 40.3 (34.3-46.9)
65-79 years 49.6 (40.2-60.6) 88.2 (82.9.5-93.7) 71.0 (58.1-85.9) 43.1 (34.1-53.7)
80+ years 27.9 (16.8-43.6) 61.4 (55.5-67.8) 35.3 (21.6-53.6) 46.1 (30.4 -67.0)
Period: 1992-2003
Age-adjusted trend (APC %)
b 2.8* -0.1 1.9* 0.4
Age-specific trend (APC %)
20-34 years 9.2* 6.4* 10.5* 4.4
35-49 years 1.4 1.0 5.6* 2.4*
50-64 years 2.8* 0.5 2.2* 1.9*
65-79 years 3.3* -1.4* 1.5 -2.6*
80+ years 0.8 -3.8*^ -2.6* 0.1
a Annual rates presented for selected years;
b Standardized to the United States 2000 Standard population using the direct method; *p-value < 0.05;
† Not
enough cases to make estimate as no cases were reported for some years; ^Period 1992-1997 the APC = 4.1* and 1997-2003 the APC = -3.8*.
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dren in 1932 to 2.1 children in 1998 [28,29]. In fact,
Puerto Rico’s current fertility rate (2.0 children per
woman) is slightly lower than that of the United States
(2.1 per woman) [30]. The fact that the median age of
menarche has decreased in young Puerto Rican women
(13.2 years: 1935-1939 to 12.7 years: 1965-1967) [28,31]
may in part also explain the observed increases in the
incidence trends in this population, as these increase the
lifetime exposure to exogenous and endogenous estro-
gens, respectively [32]. Nonetheless, although historical
data is limited, studies suggest that age at natural
menopause, another factor related to endometrial cancer
risk [2], is currently similar between Puerto Rican
women in Puerto Rico (51.3 years) [31] and women
from the United States (51.4 years) [30]; suggesting that
the time of exposure to endogenous estrogen is similar
in these populations [33].
Regarding hormone therapy, after reports of increased
risk of endometrial cancer with use of estrogen replace-
ment therapy in the 1980’s, declines in prescriptions for
estrogen and subsequent declines in endometrial cancer
incidence were observed in the United States [34].
Although recent evidence supports that hormone
Table 2 Age-adjusted and age-specific mortality
a rates and trends from endometrial cancer by racial/ethnic group,
1992-2003
b
Puerto Rico NHW NHB Hispanics
Year: 1992
Age-adjusted rate × 100,000
(95% CI)
b, c 5.5 (4.2-7.1) 5.7 (5.5-5.8) 10.0 (9.4-10.7) 4.3 (3.7-4.9)
Age-specific rate (95% CI)
20-34 years 0.7 (0.2-2.2) 0.1 (0.0-0.1) 0.3 (0.1-0.5) 0.1 (0.0-0.3)
35-49 years 1.1 (0.3-2.9) 0.8 (0.7-0.9) 1.2 (0.8-1.6) 1.2 (0.8-1.8)
50-64 years 4.5 (2.2-8.1) 5.9 (5.5-6.5) 11.4 (9.9-13.1) 5.4 (4.1-7.0)
65-79 years 18.6 (12.4-26.9) 20.2 (19.4-21.0) 38.1 (34.7-41.8) 13.7 (10.8-17.1)
80+ years 31.1 (17.0-52.2) 32.2 (30.6-33.9) 46.7 (40.0-54.2) 19.4 (13.1-27.7)
Year: 2003
Age-adjusted rate × 100,000
(95% CI)
b, c 6.9 (5.6-8.4) 5.6 (5.4-5.7) 10.0 (9.4-10.6) 4.2 (3.7-4.7)
Age-specific rate (95% CI)
20-34 years 0.2 (0.0-1.3) 0.1 (0.0-0.1) 0.2 (0.1-0.4) 0.1 (0.0-0.2)
35-49 years 2.7 (1.3-4.8) 0.9 (0.8-1.0) 1.3 (1.0-1.7) 1.0 (0.7-1.4)
50-64 years 6.8 (4.3-10.2) 6.6 (6.3-7.0) 11.5 (10.2-12.9) 4.6 (3.7-5.7)
65-79 years 21.8 (15.7-29.4) 19.0 (18.2-19.8) 38.0 (34.7-41.4) 13.1 (10.9-15.7)
80+ years 35.3 (22.6-52.5) 29.6 (28.2-31.1) 45.4 (39.7-51.7) 24.5 (19.0-31.0)
Period: 1992-2003
Age-adjusted trend (APC %)
c -1.5 -0.1 0.1 0.1
Age-specific trend (APC %)
20-34 years ††††
35-49 years -3.6 2.1* 1.3 -1.0
50-64 years 0.1 0.9* -0.5 -0.4
65-79 years -1.1 -0.7* 0.2 -0.1
80+ years -1.4 -0.6* -0.1 1.6
a Mortality statistics were based on Corpus and Uterus, NOS Cancer;
b Annual rates presented for selected years;
c Standardized to the United States 2000
Standard population using the direct method; *p-value < 0.05;
† Not enough cases to make estimate as no cases were reported for some years; ^Period 1992-1997 the APC = 4.1* and 1997-2003 the APC = -3.8*.
Table 3 Age-standardized incidence and mortality rates (per 100,000) for endometrial cancer during 1999-2003
Age Standardized Rate (ASR) Standardized Relative Ratio*(SRR
a)
Puerto Rico Hispanics NHW NHB Puerto Rico
vs. Hispanics
b
Puerto Rico
vs. NHW
b
Puerto Rico
vs. NHB
b
Incidence 18.46 19.62 33.13 20.28 0.94 (0.87-1.01) 0.56 (0.53-0.59)* 0.91 (0.84-0.98)*
Mortality 5.13 4.43 5.53 10.04 1.15 (1.03-1.30)* 0.93 (0.83-1.03) 0.51 (0.46-0.57)*
a The ratio of two ASR (US 2000) with 95% confidence interval between parentheses;
b Reference group; * Statistically significant.
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omy should consist of both estrogen and progesterone,
to reduce the risk of endometrial hyperplasia [35], accel-
erated decreases in the use of hormone therapy have
again been observed in the United States after the 2002
Women’s Health Initiative report of greater harm than
benefit of combined conjugated equine estrogens plus
progestin [36]. Nonetheless, to our knowledge, popula-
tion-based data on the impact of these more recent
decreases in hormone therapy use on endometrial can-
cer trends in the United States has not yet been pub-
lished and in fact, these changes in hormone use would
not impact the time period studied in this analysis
(1992-2003). For Puerto Rico, the fact that no popula-
tion-based data on historical use of hormone therapy
has been published, limits our ability to hypothesize on
the impact of hormone therapies on endometrial cancer
incidence trends in this population. Given the increasing
trends observed in the incidence of endometrial cancer
in Puerto Rico, particularly among younger women,
future analytical epidemiologic studies should assess the
impact of changes in lifestyle factors in the occurrence
of endometrial cancer in Puerto Rico. Also, multiethnic
studies should access the reasons for the increases in
endometrial cancer that were also observed among
NHW, NHB and Hispanic young women in the United
States.
Despite increasing incidence trends, mortality trends
of endometrial cancer in Puerto Rico have remained
relatively constant. These constant mortality trends were
also seen among all age-groups of Hispanic and NHB
women in the United States, and are consistent with
SEER data from similar time periods [37]. Decreasing
trends in mortality from endometrial cancer were only
observed among NHW women aged 65 years and older.
These results suggest that contrary to NHW, advances
in treatment have not significantly benefited Puerto
Ricans and other racial/ethnic minority populations in
the United States. Disease stage at diagnosis, histologic
type of the tumor, access to care, and differences in
pharmacogenomics and response to treatment across
these racial/ethnic groups should be evaluated in order
to determine their impact on mortality trends.
Regarding the SRR’s, consistent with studies per-
formed in the 70’sa n d8 0 ’s [4,5], the incidence of endo-
metrial cancer in Puerto Rico from 1999-2003 was
significantly lower than that of NHW and NHB.
Although we observed similar incidence rates between
Puerto Rican and Hispanic women, recent studies sug-
gest that Puerto Ricans are the Hispanic subgroup most
affected by cancer in the United States [38], and that
endometrial cancer in island Puerto Ricans is in fact
lower than that of mainland Puerto Ricans [38,39]; a
pattern also consistent with historical data [5]. Thus,
future analytic studies between mainland and island
Puerto Ricans should help elucidate the risk factors and
the potential gene-environment interactions that occur
a m o n gP u e r t oR i c a n so n c et h e ym i g r a t et ot h ec o n t i -
nental United States, and that result in increased inci-
dence of the disease in this group. Our study also
showed that women in Puerto Rico had higher age-
adjusted mortality rate from endometrial cancer from
1999-2003 than Hispanic women living in the United
States (although similar to NHW and lower than that of
NHB). This result also warrants further attention and
elucidation, particularly given the lack of data compar-
ing endometrial cancer mortality statistics across these
populations.
Survival
Puerto Rican and NHB women had a poorer 5-year sur-
vival from endometrial cancer compared to NHW and
Hispanic women in the United States (1992 to 2002).
These results are consistent with previous studies which
have reported a survival disadvantage among NHB
women compared to NHW women [40]. A potential
explanation for this disparity is differences in medical
access and treatment [40]. Nonetheless, disparities seem
to remain independent of treatment, suggesting that
other factors, including cancer biology, socioeconomic
and cultural factors should be evaluated [41]. We also
observed that although the SRR for mortality showed
that Puerto Ricans and NHW had similar mortality
rates from endometrial cancer, the hazard ratio from
the age-adjusted Cox model showed that NHW had a
clear advantage over Puerto Ricans regarding their five-
year survival. The lower five-year survival from endome-
trial cancer among Puerto Ricans in our study (as com-
pared to NHW), suggests a health disparity for this
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Figure 1 Five-year observed survival of endometrial cancer by
racial/ethnic group: 1992-2002. Log-rank test X
2 = 817.94, p <
0.0001. Age-adjusted Cox proportional Hazards model: Hispanic: HR
= 0.63, 95% CI = 0.56-0.71; NHW: HR = 0.47, 95% CI = 0.43-0.52; NHB:
HR = 1.22, 95% CI = 1.09-1.36; Puerto Rico: HR = 1.00 (reference).
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in terms of stage at diagnosis and associated comorbid-
ities. Given the limited availability of data, future studies
should define what social and clinical indicators might
be influencing the observed disparities in endometrial
cancer survival in Puerto Rico. In addition, given that
research suggests that women with private medical
insurance coverage are diagnosed at an earlier stage, and
their pattern of care differs from those of women with
other types of health insurance [42], future studies
should also address the impact of the introduction of
the Health Care Reform legislation in Puerto Rico in
1993 on endometrial cancer survival. This model shifted
medically indigent persons from direct care by public
sector institutions to managed care arrangements
through the private sector [43,44]; even though this
model (which covers approximately 40% of the popula-
tion) made available health insurance for underserved
populations, it restricts the referrals to specialists and
limits the use of more expensive diagnostic and treat-
ment options [44].
A limitation of this study is the lack of adjustment by
hysterectomy rates which might have resulted in an
underestimation in our estimates of disease occurrence
[45]. The prevalence of hysterectomy in the United
States (21%-24%) [46], and in Puerto Rico is high (13.1%
for women 35 to 49 years and 32.5% for women ≥ 50
years; [unpublished data, Estudio Continuo de Salud,
Ramos G. et al, 2002]. Also, although common, the
practice of combining corpus and NOS categories, some
of which are of cervical origin, could have overestimated
our statistics of endometrial cancer mortality. Finally,
even though Puerto Rico is a Hispanic population, His-
panics in the United States constitute an heterogeneous
group of persons from a variety of Hispanic origins (i.e.
Mexican, Cubans, Puerto Ricans), that in fact show sub-
stantial variability in cancer rates across subpopulations
[38]. Also, Hispanics may differ by degree of accultura-
tion or socioeconomic status and cancer occurrence and
risk factors can vary among Hispanics because of regio-
nal, behavioral, or genetic differences [47]. Thus, we
highlight that the Hispanic population residing in the
United States described in this study is not directly
comparable to the Puerto Rican population living in
Puerto Rico; nonetheless, the comparison between these
and other racial/ethnic groups helps to further under-
stand health disparities among racial/ethnic minorities
in the United States.
Conclusion
Our study expands the knowledge of the burden of
endometrial cancer in Puerto Rico and serves as a
baseline for the development of additional endometrial
cancer research as well as cancer prevention and
control strategies in the island. Our finding of an
increased incidence of endometrial cancer in Puerto
Rico, especially among younger cohorts, suggests that
interventions that decrease known risk factors, such as
obesity and diabetes, may be critical to reversing this
trend. Future studies including demographic, lifestyle,
clinical and genetic variables are needed to better
understand what factors have influenced disparities in
endometrial cancer occurrence and survival among
Puerto Ricans. These studies will be essential to
develop targeted public health intervention efforts and
public policy for both island and mainland Puerto
Ricans.
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